CB 1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 657-668

  Mukhopadhyay, Partha ^a   Pan, Hao ^a,b   Rajesh, Mohanraj ^a   Bátkai, Sándor ^a   Patel, Vivek ^a   Harvey White, Judith ^a   Mukhopadhyay, Bani ^a   Haskó, György ^c   Gao, Bin ^a   MacKie, Ken ^d   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Cannabinoid receptors; Endocannabinoids; Nephropathy

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 4 HYDROXYNONENAL; CANNABINOID 1 RECEPTOR; CISPLATIN; CREATININE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; POLY(ADENOSINE DIPHOSPHATE RIBOSE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RIMONABANT; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UREA; 2 ARACHIDONOYLGLYCEROL; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; MORPHOLINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVATION; GENE DELETION; HISTOPATHOLOGY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MOUSE; NEPHRITIS; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; INFLAMMATION; KIDNEY; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONIC ACIDS; CELL DEATH; CISPLATIN; DISEASE MODELS, ANIMAL; GLYCERIDES; INFLAMMATION; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MORPHOLINES; NEPHRITIS; OXIDATIVE STRESS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 77952646902     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00769.x     Document Type: Article

References (67)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 : S1 209.
2. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P et al. (2007). Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21 : 1788 1800.
3. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH (2004). Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88 : 1159 1167.
4. Bifulco M, Pisanti S (2009). End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. Nat Rev Drug Discov 8 : 594.
5. 1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism (doi:10.1016/j. metabol.2009.09.018).
6. Caraceni P, Pertosa AM, Giannone F, Domenicali M, Grattagliano I, Principe A et al. (2009). Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 58 : 1135 1143.
7. Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J (2004). Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 4 : 20.
8. Chirino YI, Trujillo J, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Cruz C, Bobadilla NA et al. (2008). Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett 176 : 48 57.
9. Dalton GD, Bass CE, Van Horn C, Howlett AC (2009). Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 8 : 422 431.
10. Davis CA, Nick HS, Agarwal A (2001). Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 12 : 2683 2690.
11. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100 : 1538 1546.
12. Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 : 438 455.
13. Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, Hennuyer N et al. (2009). Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 29 : 12 18.
14. Engeli S (2008). Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 20 : 110 115.
15. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H et al. (2007). Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322 : 8 15.
16. Ferdinandy P (2006). Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 148 : 1 3.
17. Ferdinandy P, Schulz R (2003). Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138 : 532 543.
18. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C et al. (2007). Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46 : 122 129.
19. Han KH, Lim S, Ryu J, Lee CW, Kim Y, Kang JH et al. (2009). CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 84 : 378 386.
20. Ishii Y, Sakamoto T, Ito R, Yanaga K (2009). F(2)-isoprostanes and 2-arachidonylglycerol as biomarkers of lipid peroxidation in pigs with hepatic ischemia/reperfusion injury. J Surg Res (in press).
21. Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L et al. (2007). Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72 : 1345 1357.
22. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M et al. (2005). Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 : 742 755.
23. Kadoi Y, Goto F (2006). Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine. J Anest 20 : 284 289.
24. Liaudet L, Vassalli G, Pacher P (2009). Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front Biosci 14 : 4809 4814.
25. Lim SY, Davidson SM, Yellon DM, Smith CC (2009). The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol 104 : 781 792.
26. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S et al. (2008). Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54 : 1 7.
27. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S et al. (2008). CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153 : 286 289.
28. Mach F, Montecucco F, Steffens S (2008). Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 153 : 290 298.
29. Malfitano AM, Laezza C, Pisanti S, Gazzerro P, Bifulco M (2008). Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol 153 : 1003 1010.
30. Matsushima H, Yonemura K, Ohishi K, Hishida A (1998). The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 131 : 518 526.
31. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, Hasko G et al. (2007). Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50 : 528 536.
32. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L et al. (2009). Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296 : H1466 H1483.
33. Mukhopadhyay P, Mohanraj R, Pan H, Patel V, Mukhopadhyay B, Batkai S et al. (2010a). Cannabinoid-2 receptor limits inflammation, oxidative-nitrosative stress and cell death in nephropathy. Free Radic Biol Med 48 : 457 467.
34. Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, Liaudet L et al. (2010b). CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 85 : 773 784.
35. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ (2004). Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129 : 743 750.
36. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. (2005). Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 : 1298 1305.
37. Pabla N, Dong Z (2008). Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73 : 994 1007.
38. Pacher P (2009). Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler Thromb Vasc Biol 29 : 7 9.
39. Pacher P, Gao B (2008). Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol 294 : G850 G854.
40. Pacher P, Hasko G (2008). Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153 : 252 262.
41. Pacher P, Steffens S (2009). The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 31 : 63 77.
42. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 : 389 462.
43. Pacher P, Beckman JS, Liaudet L (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 : 315 424.
44. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G (2008). Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 52 : 601 607.
45. Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B et al. (2009a). Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 328 : 708 714.
46. Pan H, Shen Z, Mukhopadhyay P, Wang H, Pacher P, Qin X et al. (2009b). Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 296 : F496 F504.
47. Pertwee RG (2002). Cannabinoids and multiple sclerosis. Pharmacol Ther 95 : 165 174.
48. Pertwee RG (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156 : 397 411.
49. Pisanti S, Bifulco M (2009). Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 60 : 107 116.
50. Racz I, Tory K, Gallyas F Jr., Berente Z, Osz E, Jaszlits L et al. (2002). BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 63 : 1099 1111.
51. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW et al. (2007a). CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293 : H2210 H2218.
52. Rajesh M, Pan H, Mukhopadhyay P, Batkai S, Osei-Hyiaman D, Hasko G et al. (2007b). Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82 : 1382 1389.
53. Ramesh G, Reeves WB (2002). TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110 : 835 842.
54. Ries F, Klastersky J (1986). Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8 : 368 379.
55. Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC et al. (2009). Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer 125 : 996 1003.
56. Schafer A, Pfrang J, Neumuller J, Fiedler S, Ertl G, Bauersachs J (2008). The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 154 : 1047 1054.
57. Schrier RW (2002). Cancer therapy and renal injury. J Clin Invest 110 : 743 745.
58. Sommer C, Schomacher M, Berger C, Kuhnert K, Muller HD, Schwab S et al. (2006). Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol 112 : 277 286.
59. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 : 782 786.
60. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K et al. (2009). Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119 : 28 36.
61. Szabo C, Ischiropoulos H, Radi R (2007). Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6 : 662 680.
62. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L et al. (2006). CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12 : 671 676.
63. Villanueva A, Yilmaz MS, Millington WR, Cutrera RA, Stouffer DG, Parsons LH et al. (2009). Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock 32 : 614 620.
64. Wang D, Lippard SJ (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4 : 307 320.
65. Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S et al. (2002). Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet Pathol 39 : 322 333.
66. Zhang B, Ramesh G, Norbury CC, Reeves WB (2007). Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 72 : 37 44.
67. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D et al. (2009). Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 4 : 249 259.